ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China

Yang, Rui-Xu; Zou, Zheng-Sheng; Zhong, Bi-Hui; Deng, Hong; He, Fang-Ping; Shi, Jun-Ping; Zhao, Cai-Yan; Mi, Yu-Qiang; Zhou, Yong-Jian; Di, Fu-Sheng; Zheng, Rui-Dan; Du, Qin; Shang, Jia; Popovic, Branko; Chen, JinJun*; Fan, Jian-Gao*南方医科大学; 上海交通大学; 河北医科大学; 浙江大学; 中山大学; 杭州师范大学; 1; 5
Hepatobiliary & Pancreatic Diseases International2021-10DOI: 10.1016/j.hbpd.2021.06.002
9被引8阅读
引用收藏
分享

摘要

Background: This study aimed to assess the association between metabolic syndrome (MetS) and severity of nonalcoholic fatty liver disease (NAFLD), and to discuss the pathological relevance of the diagnostic criteria in metabolic (dysfunction) associated fatty liver disease (MAFLD). @@@ Methods: This was a multicenter, cross-sectional study. Patients with NAFLD confirmed by liver biopsy were enrolled between July 2016 and December 2018 from 14 centers across the mainland of China. Anthropometric and metabolic parameters were collected to assess the pathological relevance. @@@ Results: Of 246 enrolled patients with NAFLD, 150 (61.0%) had the comorbidity of MetS. With the increase of metabolic components, the proportions of nonalcoholic steatohepatitis (NASH) and significant fibrosis were notably increased. The comorbid three metabolic components significantly increased the proportion of NASH, and further increase of metabolic components did not increase the proportion of NASH. However, the increase of metabolic components was parallel to the increase of the proportion of liver fibrosis. Among the 246 patients, 239 (97.2%) met the diagnostic criteria of MAFLD. Although non-MAFLD patients had less NASH, they present with similar proportion of significant fibrosis and cirrhosis. In the diagnostic criteria of MAFLD, BMI >= 23 kg/m(2) was related to NASH (Mantel-Haenszel Common Estimate OR: 2.975; 95% CI: 1.037-8.538; P = 0.043), and T2DM was related to significant fibrosis (Mantel-Haenszel Common Estimate OR: 2.531; 95% CI: 1.388-4.613; P = 0.002). The homeostasis model assessment of insulin resistance (HOMA-IR) >= 2.5 was the most significant factor for NASH (OR: 4.100; 95% CI: 1.772-9.487; P = 0.001) and significant factor for liver fibrosis (OR: 2.947; 95% CI: 1.398-6.210; P = 0.004) after the adjustments of the BMI and diabetes. @@@ Conclusions: Metabolic dysregulations are important risk factors in NAFLD progression. The insulin resistance status may play a predominant role in the progression in MAFLD patients.

学科与关键词

关键词
Nonalcoholic fatty liver diseaseMetabolic syndromeInsulin resistance
相关
加载中…
  • Discrepancies between Nonalcoholic and Metabolic- associated Fatty Liver Disease by Multiple Steatosis Assessment
    Shao, Congxiang; Ye, Junzhao; Li, Xin; Lin, Yansong; Feng, Shiting; Liao, Bing; Wang, Wei; Gong, Xiaorong*; Zhong, Bihui*Journal of Clinical and Translational Hepatology, 2022.被引 3
  • Metabolic Disorders Combined with Noninvasive Tests to Screen Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
    Shi, Yi-Wen; He, Fang-Ping; Chen, Jin-Jun; Deng, Hong; Shi, Jun-Ping; Zhao, Cai-Yan; Mi, Yu-Qiang; Zou, Zheng-Sheng; Zhou, Yong-Jian; Di, Fu-Sheng; Zheng, Rui-Dan; Du, Qin; Shang, Jia; Yang, Rui-Xu; Popovic, Branko; Zhong, Bi-Hui*; Fan, Jian-Gao*Journal of Clinical and Translational Hepatology, 2021, 9(5): 607-614.被引 4
  • The presence of NAFLD in nonobese subjects increased the risk of metabolic abnormalities than obese subjects without NAFLD: a population-based cross-sectional study
    Hu, Ping-Fang; Zeng, Xin; Zou, Zi-Yuan; Tang, Wei; Guo, Yi-Bin; Yuan, Zong-Li; Shi, Pei-Mei; Tan, Yu; Song, Yan; Shi, Yong-Quan*; Xie, Wei-Fen*HEPATOBILIARY SURGERY AND NUTRITION, 2021, 10(6): 811-+.被引 12
查看全部 →

发表信息

论文状态
公开发表
期刊
Hepatobiliary & Pancreatic Diseases International
发表日期
2021-10
卷期
第 20 卷, 第 5 期
页码
426-432
DOI
10.1016/j.hbpd.2021.06.002
语言
ENGLISH
期刊收录
CSCD-C.CAST-E
期刊等级
3区
成果收录
SCIE
资助标注
Sanofi (China) Invest-ment Co., Ltd.

作者

  • Y

    Yang, Rui-Xu (第一作者)

    shanghai jiao tong univ

  • Z

    Zou, Zheng-Sheng

    5 · chinese peoples liberat army gen hosp

查看全部 16 位作者收起作者
  • Z

    Zhong, Bi-Hui

    1 · sun yat sen univ

  • D

    Deng, Hong

    sun yat sen univ

  • H

    He, Fang-Ping

    1 · 2 · xinjiang med univ

  • S

    Shi, Jun-Ping

    hangzhou normal univ

  • Z

    Zhao, Cai-Yan

    hebei med univ

  • M

    Mi, Yu-Qiang

  • Z

    Zhou, Yong-Jian

    1

  • D

    Di, Fu-Sheng

    third cent hosp tianjin

  • Z

    Zheng, Rui-Dan

  • D

    Du, Qin

    2 · zhejiang univ

  • S

    Shang, Jia

    henan prov peoples hosp

  • P

    Popovic, Branko

  • C

    Chen, JinJun (通讯)

    southern med univ

  • F

    Fan, Jian-Gao (通讯)

    shanghai jiao tong univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417